ERBB2 and neoplasm: A monoclonal antibody against the external epitope of HER-2, that is, trastuzumab, is used for therapy of breast cancer patients whose tumours express high levels of HER-2, that is, 2+ and 3+ US Food and Drug Administration-approved category (Press et al, 2002; Ross et al, 2003).